Loading stock data…
CYCN
$3.11-0.02 (-0.64%)
Market OpenUpdated 10:47 AM EDT
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cyclerion Therapeutics, Inc. in the Healthcare sector is trading at $3.13. Wall Street consensus targets $8.00 (1 analysts), implying a +155.6% move over the next 12 months. The stock is currently 63% below its 52-week high of $8.48, remaining 51.2% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +155.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$3.11
Potential Downside
0%
Whystock Fair Value$3.11
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. It is developing Olinciguat, an orally adminis...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$13.25M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.89
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-38.83%
Volume
Today's trading volume
25,948
Recent News
Cyclerion Therapeutics (CYCN) Merges With Korsana Biosciences to Advance Alzheimer’s Pipeline
Cyclerion Therapeutics Inc. (NASDAQ:CYCN) is one of the 10 Unstoppable Stocks That Could Double Your Money. Cyclerion Therapeutics Inc. (NASDAQ:CYCN) is one of the unstoppable stocks that could double your money. On April 1, Cyclerion and Korsana Biosciences entered into a definitive merger agreement to form a combined entity operating under the name Korsana Biosciences, […]
Penny Stock CYCN Surged More Than 300% Yesterday. Why, And Should You Chase the Rally Here?
Cyclerion stock soared on a merger agreement with privately held Korsana Biosciences. But there are ample reasons for disciplined investors to avoid chasing the rally in CYCN shares.
Top Midday Gainers
Cyclerion Therapeutics (CYCN) and Korsana Biosciences, a privately-held biotechnology firm, said Wed
BC-Most Active Stocks
HIVE Digital Technologies Ltd. 18,936,738 3.09
Akebia Therapeutics Sets Rare Kidney Drug Plan After Q32 Bio Deal
Akebia Therapeutics (AKBA) said Monday that it has built a rare kidney disease pipeline around a com